“What gets me excited about digitally derived endpoints is the many promises they offer to improve the way we measure a patient’s lived experience with their disease and ultimately better inform regulatory and HTA decisions. I know there are gaps in the ecosystem, but I see us already working together to close these gaps. Initiatives such as DEEP or the newly launched IHI go absolutely in the right direction. I look to a future where pre-competitive collaborations and efficient regulatory procedures for novel endpoints are the norm and where patients directly benefit from it!”
Comments